ArticleNature cancer2024
Threonine fuels glioblastoma through YRDC-mediated codon-biased translational reprogramming.
Open access · greenAbstract read
In one paragraph
Article in Nature cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
7.5field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 33 citations in OpenAlex.
- Inferring translational efficiency from transcriptomes improves noncanonical neoantigen prioritization and cancer patient stratification.NPJ precision oncology · 2026Article
- Anticodon loop remodeling and D-stem shape drive the specific recognition of ANN-decoding tRNAs for t6A modification.Nucleic acids research · 2026Article
- IQGAP3 bridges matrix stiffness with glioma stem cell maintenance and radioresistance by stabilizing SOX2.Nature communications · 2026Article
- Targeting YRDC blocks codon-biased FABP7 translation and lipid droplet formation to overcome chemoresistance in glioblastoma.Oncogene · 2026Article
- Advancements in Inorganic Chiral Nanomaterials for Anti-Tumor Immunotherapy.Cancer science · 2026Review
- Amino Acids as Targets for Immunotherapy against Solid Tumors.Cell biochemistry and biophysics · 2026Review
- G/C-ending and synonymous codon bias define functional translational programs that shape human tissue and cancer proteomes.NAR genomics and bioinformatics · 2026Article
- Cancer stem cells synthesize proline to attenuate oxidative stress.The Journal of clinical investigation · 2026Article
- Spatial single-cell landscape of tumor-associated macrophages and their crosstalk with the tumor microenvironment.Cell discovery · 2026Article
- Catalytic and regulatory basis of tRNA tNature communications · 2026Article
- The metabolic profiles of cancer stem cells.Stem cell research & therapy · 2026Review
- tRNA modifications in cancer: from molecular mechanisms to clinical translation.Biomarker research · 2026Review
- Targeting Tumour Microtubes to Disrupt Glioma Networks.Research square · 2026Article
- Targeting tRNA-dependent tyrosine usage unveils a metabolic vulnerability in hepatocellular carcinoma.Nature communications · 2026Article
- Disruption of tRNA threonylation triggers RIG-I mediated anti-tumour immune response.Nature communications · 2026Article
- Tissue-specific role of dTrmO in threonine decoding during Drosophila melanogaster development.Biological research · 2026Article
- Stable isotope tracing in human plasma-like medium reveals metabolic and immune modulation of the glioblastoma microenvironment.Neuro-oncology · 2026Article
- An alternative EGFR activation by patient-derived R252C mutation promotes cancer progression.Nature communications · 2026Article
- Integration of omics data in the diagnosis and therapy of glioblastoma.Brain pathology (Zurich, Switzerland) · 2026Review
- Beyond Glucose and Lipids: The Pivotal Role of Amino Acid Reprogramming in Shaping the Tumor Microenvironment and Guiding the Development of Novel Therapeutics.International journal of medical sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 5 institutions in 2 countries.
Xujia WuHillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0002-6904-0778
Huairui YuanHillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Qiulian WuHillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Yixin GaoDepartment of Neurosurgery, the First Affiliated Hospital of Sun Yat-sen University, Guangdong Provincial Key Laboratory of Brain Function and Disease, Guangdong Translational Medicine Innovation Platform, Guangzhou, China.
Tingting DuanHillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0002-4482-5587
Kailin YangDepartment of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA.
Tengfei HuangHillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Shuai WangHillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Fanen YuanHillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Derrick LeeHillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Suchet TaoriHillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Tritan PluteDepartment of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Søren HeisselProteomics Resource Center, the Rockefeller University, New York, NY, USA.
Hanan AlwaseemProteomics Resource Center, the Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0002-4946-1436
Michael Isay-Del ViscioProteomics Resource Center, the Rockefeller University, New York, NY, USA.
Henrik MolinaProteomics Resource Center, the Rockefeller University, New York, NY, USA.
Sameer AgnihotriDepartment of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Dennis J HsuHillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Nu ZhangDepartment of Neurosurgery, the First Affiliated Hospital of Sun Yat-sen University, Guangdong Provincial Key Laboratory of Brain Function and Disease, Guangdong Translational Medicine Innovation Platform, Guangzhou, China. zhangnu2@mail.sysu.edu.cn.ORCID http://orcid.org/0000-0002-2817-7065
Jeremy N RichHillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. drjeremyrich@gmail.com.ORCID http://orcid.org/0000-0001-7845-5302
UPMC Hillman Cancer Center · USRockefeller University · USUniversity of Pittsburgh · USSun Yat-sen University · CNCleveland Clinic · US
Funding
VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD · 1988 to 2026
$158.0MDynamic Complexity of Brain Tumor Stem Cells (R35CA197718)R35CA197718 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI RICH, JEREMY N · 2015 to 2021
$6.4MMetabolic Regulation of Glioblastoma EpitranscriptomicsR01CA268634 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Sameer Agnihotri, JEREMY N RICH · 2022 to 2026
$2.9MTargeting the Circadian Rhythm in Glioblastoma Stem Cells (R01CA238662)R01CA238662 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KAY, STEVE A, RICH, JEREMY N · 2020 to 2024
$2.8MDual Targeting of Brain Tumor Initiating Cells through Inhibition of BMI1 and EZH2 (R01NS103434)R01NS103434 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI RICH, JEREMY N · 2017 to 2021
$1.7MNCI NIH HHS P30 CA047904NCI NIH HHS R01 CA238662NCI NIH HHS R01 CA268634NCI NIH HHS R35 CA197718NINDS NIH HHS R01 NS103434U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01CA238662U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01CA268634U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01NS103434U.S. Department of Health & Human Services | National Institutes of Health (NIH) R35CA197718
Abstract
Cancers commonly reprogram translation and metabolism, but little is known about how these two features coordinate in cancer stem cells. Here we show that glioblastoma stem cells (GSCs) display elevated protein translation. To dissect underlying mechanisms, we performed a CRISPR screen and identified YRDC as the top essential transfer RNA (tRNA) modification enzyme in GSCs. YRDC catalyzes the formation of N
Indexed as
GlioblastomaThreonineAnimalsBrain NeoplasmsCell Line, TumorCodonHumansMiceNeoplastic Stem CellsProtein BiosynthesisRNA, TransferXenograft Model Antitumor AssaysCodonRNA, TransferThreonine
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.